Otsuka and Click Therapeutics Announce the U.S. Food and Drug Administration (FDA) Clearance of Rejoyntm, the First Prescription Digital Therapeutic Authorized for the Adjunctive Treatment of Major Depressive Disorder (MDD) Symptoms

Otsuka Pharmaceutical, Co. Ltd. (Otsuka) and Click Therapeutics, Inc., (Click) announce that the U.S. Food and Drug Administration (FDA) has cleared Rejoyntm (developed as CT-152), the first prescription digital therapeutic authorized for the...

Related Keywords

Tokyo ,Japan ,United States ,Brian Iacoviello ,John Kraus ,David Benshoof Klein ,Linkedin ,World Health Organization ,Patient Health Questionnaire ,Otsuka Pharmaceutical Development Commercialization Inc ,Otsuka Pharmaceutical Co Ltd ,National Institute Of Mental Health ,Otsuka America Inc ,Treatment In Behavioral Health ,Drug Administration ,Click Therapeutics Inc ,Otsuka Holdings Co Ltd ,Otsuka America Pharmaceutical Inc ,Twitter ,Otsuka Pharmaceutical Company Ltd ,Product Service ,Icahn School Of Medicine At Mount Sinai ,Digital Therapeutics Alliance ,Click Therapeutics Announce ,First Prescription Digital Therapeutic Authorized ,Adjunctive Treatment ,Major Depressive Disorder ,Click Therapeutics ,Depression Rating Scale ,Clinical Global Impression ,Clinician Brief ,Icahn School ,Mount Sinai ,Emotional Faces Memory Task ,Faces Memory ,Mirai Clinical ,Mirai Trial ,Statistical Manual ,Mental Disorders ,Fifth Edition ,About Major Depressive ,National Institute ,Otsuka Pharmaceutical Development ,Otsuka America Pharmaceutical ,Otsuka Pharmaceutical Company ,Digital Therapeuticstm ,World Health ,Published March ,Published July ,Accessed February ,